MRMaryluz Rol

Maryluz Rol

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Maryluz Rol has a total of 158 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Estimating cervical precancer and cancer risk based on HPV testing, cervical cytology and colposcopic impression: results from the ESTAMPA multicentric study in Latin America

    by Joan Valls, José Jerónimo, Gino Venegas, Marcela Celis, Mauricio González, Carlos Sosa, Jorge Luis Santin, Marina Ortega, Ana Soilán, Elmer Turcios, et al.

  • Open Access

    Clinical Validation of Four Point‐of‐Care High‐Risk HPV Assays, Including Two Reduced‐Valency Assays, for Cervical Cancer Screening in Low‐Resource Settings

    by Neerja Bhatla, MaryLuz Rol, Seema Singhal, Showket Hussain, Anushree Patil, Pranay Tanwar, Shalini Singh, Vikrant M. Bhor, Kiran Munne, Richa Vashishtha, et al.

    Persistent infection with high‐risk human papillomavirus (HR‐HPV) is the necessary cause of cervical cancer, with approximately 95% of cases attributable to eight most carcinogenic HPV types (16/18/31/33/35/45/52/58). Several HPV assays have recently been developed in India for use in cervical cancer screening, including reduced‐valency tests targeting seven/eight oncogenic HPV types. We evaluated the clinical accuracy and reproducibility of four such assays: PathoDetect‐HPV‐14, HPV‐Q (14 types), Truenat‐HR‐HPV‐Plus (8 types), and PathoDetect‐HPV‐7 (7 types). Using the VALGENT framework, 1159 cervical samples from the ESTAMPA study conducted in Argentina and Costa Rica were analysed with the new assays. The samples included 97 cases of CIN2+ (19 CIN2, 72 CIN3, and 6 cancers). Assay performance was compared in a blinded manner with established reference tests (Cobas‐4800 and Allplex‐HPV‐HR) and reduced‐valency comparators. Sensitivity, specificity, agreement, and repeatability were assessed. Truenat‐HR‐HPV‐Plus demonstrated a sensitivity of 80.4% (95% CI: 71.1–87.8) and specificity of 91.5% (95% CI: 89.5–93.2) for CIN2+. It met IARC validation criteria and showed non‐inferior performance to Allplex‐HPV‐HR‐8, with relative sensitivity of 1.03 (95% CI: 0.96–1.09) for CIN2+ and 1.00 (95% CI: 0.96–1.04) for CIN3+, and relative specificity of 0.99 (95% CI: 0.97–1.00) and 0.98 (95% CI: 0.97–1.00), respectively. Repeatability was 93.3% (κ = 0.79). PathoDetect‐HPV‐7 showed lower sensitivity (68.1%) with specificity of 89.0%. HPV‐Q and PathoDetect‐HPV‐14 did not meet validation criteria. This study represents the first formal validation of reduced‐valency HPV assays and demonstrates that Truenat‐HR‐HPV‐Plus provides robust clinical performance with higher specificity than 14‐valent assays, supporting its potential to improve screening efficiency and reduce unnecessary referrals.

  • Open Access

    Estimating Cervical Precancer and Cancer Risk Based on HPV Testing, Cervical Cytology and Colposcopic Impression: Results From the ESTAMPA Multicentric Study in Latin America

    by Joan Valls, Jose Jeronimo, Gino Venegas, Marcela Celis, Mauricio Gonzalez, Carlos Sosa, Jorge Luis Santin, Marina Ortega, Ana Soilán, Elmer Turcios, et al.

    Background: Cervical cancer is largely preventable, yet major gaps persist in detection and timely management of cervical precancer, particularly in low- and middle-income countries. Using data from the ESTAMPA multicentric study, we derived stratified absolute risk estimates for cervical precancer and cancer based on HPV testing, cervical cytology, and colposcopic impression. Methods: ESTAMPA recruited women aged 30–64 years across 12 centres in nine Latin American countries. Women were screened with HPV testing and cervical cytology. Those with positive screening results were referred to colposcopy using a standardised protocol including colposcopic impression, directed biopsies, and treatment as indicated. Women with normal colposcopy or histology less than CIN2 were recalled after 18 months for repeat HPV testing and colposcopy if HPV-positive. Absolute risks of histologically confirmed CIN3+ detected at baseline or follow-up were estimated integrating HPV testing, cytology, and colposcopic impression. Findings: 44,135 women with a valid HPV test were included, of whom 6,236 (14·1%) were HPV-positive. Overall, 764 CIN3+ lesions were detected (1·73%; 95% CI 1·61–1·86). CIN3+ risk was 12·0% (747/6,236; 95% CI 11·2–12·8) among HPV-positive women compared with 0·04% (17/37,899; 95% CI 0·03–0·07) among HPV-negative women. Among HPV-positive women, risk increased with cervical cytological severity, reaching 62·9% (95% CI 57·1–68·5) for HSIL+, 22·4% (95% CI 18·4–26·8) for LSIL, and 19·1% (95% CI 15·1–23·6) for ASC-US; a positive colposcopic impression further increased CIN3+ risk to 70·2% (95% CI 64·1–75·9), 28·5% (95% CI 23·5–34·0), and 24·5% (95% CI 19·4–30·2), respectively. Among HPV16/18-positive women, CIN3+ risk was 32·8% (95% CI 28·9–37·0) increasing to 46·2% (95% CI 40·8–51·6) when abnormal colposcopy was present. Interpretation: We confirmed a high underlying risk of CIN3+ in the Latin American population, with risk strongly stratified by HPV positivity, increasing cervical cytological severity, and positive colposcopic impression. These estimates may support WHO-aligned cervical screening and risk-based management strategies in LMICs and contribute to accelerating cervical cancer elimination.

  • 60 years of the IARC catalyzing capacity building for cancer prevention

    by Sarra Ezzemni, Frederic Lam, Lynn Al Korhani, Isabelle Battaglia, Laura Downham, Laure Dossus, Carolina Espina, Matthieu Foll, Oliver Langselius, Dominique Meunier, et al.

    Over the past 6 decades, the International Agency for Research on Cancer (IARC) has played a pivotal role in global cancer research capacity building. This study presents a comprehensive evaluation of IARC’s capacity-building initiatives with a mixed-methods approach. We integrated qualitative and quantitative data from institutional records, outcome surveys, and a career-tracking study of postdoctoral fellows. IARC’s capacity-building portfolio includes fellowships, digital-learning platforms, a summer school, and global networks such as the Global Initiative for Cancer Registry development, the Cancer Screening in 5 Continents project, and the Biobank and Cohort Building Network. Since 1966, approximately 30 000 professionals from most countries in the world have benefited from those initiatives, with a majority from low- and middle-income countries. Among tracked IARC postdoctoral fellows, since 1966, 76.5% remained in academia, and 18.7% had a role in public health policy. Qualitative findings highlight the impact of IARC training on individual careers, institutional capacity, and global cancer control strategies. IARC’s sustained investment in capacity-building has strengthened the cancer research workforce and institutional infrastructures while reducing inequalities in low- and middle-income countries. These efforts have advanced leadership, equity, and evidence-based cancer prevention. As global health challenges evolve, continued support remains essential to achieving equitable cancer control worldwide.

  • Open Access

    Exploring Human Papillomavirus 16 Long Control Region Variants in Paraguayan Women: Comparing Variant Diversity to Transcriptional Activity and Cervical Lesion Severity

    by Pamela Mongelós, Magaly Martínez, Natalia Díaz, Valéria Talpe Nunes, Adriana Valenzuela Cáceres, Alexandra Mercado-Amarilla, Mabel Miranda, Laura Bernal, Elena Kasamatsu, Malvina Páez, et al.

    Human papillomavirus Type 16 (HPV16) variants are classified into four lineages (A–D) and 16 sublineages: A1–3 (European), A4 (Asian), B1–4 and C1–4 (African), and D1–4 (Asian‐American). This study investigated the genetic HPV16 variability through sequencing of the complete long control region (LCR), in 44 cervical samples from Paraguayan women, including 19 without cervical intraepithelial neoplasia grade 2 (p < 0.05), although none remained statistically significant after correction for multiple comparisons. Notably, most of these mutations were predominantly observed in non‐A1–A3 variants. An exploratory association was observed between non‐A1–A3 variants and the presence of CIN2+ ( p = 0.0065). Functional analysis revealed that the A4 variant, detected in a woman with cancer, exhibited the highest transcriptional activity (2.34 ± 0.78), followed by D3 (0.72 ± 0.21) and A1 (0.03 ± 0.02), corresponding to samples from women with CIN3 and without lesions, respectively. In conclusion, we report for the first time the detection of an A4 HPV16 variant in Paraguay, which exhibited the highest transcriptional activity among the variants analyzed. These findings suggest potential functional differences among HPV16 variants and are consistent with a possible relevance of non‐A1–A3 variants in cervical lesion severity. However, these results should be interpreted with caution as exploratory and hypothesis‐generating.

  • Lessons Learned From Evaluation of a Human Papillomavirus Screening Pilot in Uzbekistan

    by Nargiza Zahirova, Mirzagaleb Tillyashaykhov, Dilshod Egamberdiev, Eric Lucas, Maryluz Rol, Nodira Inoyatova, Mukhabbat Akhmedova, Ilya Olkov, Richard Muwonge, Partha Basu

    PURPOSE: In 2021, Ministry of Health conducted a pilot study to screen 50,000 women with human papillomavirus (HPV) testing in Uzbekistan and assess the feasibility of national implementation. The present article describes organization of the pilot, evaluation of the program using key performance indicators (KPIs), and lessons learned. METHODS: Women age 30-55 years were invited for HPV screening via a communication campaign at 11 polyclinics in Karakalpakstan province. Samples were collected and analyzed locally in nine polyclinics using GeneXpert test. HPV-positive women were triaged with colposcopy, although colposcopists were not trained to obtain biopsies or perform treatment. Abnormal results led to further diagnostic colposcopy and treatment. Pilot data were managed using an Excel database, with quality assurance through regular monitoring visits and estimation of KPIs. RESULTS: Over 10 months, 50,000 women were tested for HPV, with 98% yielding satisfactory results and a 6.8% positivity rate. Of the HPV-positive women, 93.9% underwent triaging colposcopy, revealing abnormalities in 32.5%, although results varied by district. Diagnostic colposcopy and histopathology data were available for 87.9% of referrals. Treatment adherence was not systematically tracked. An external review showed 64.6% agreement with local histopathology, and the correlation between diagnostic colposcopy and histopathology was 53.2%. CONCLUSION: The pilot successfully recruited a large number of women and ensured high participation of the HPV-positive women in triage and diagnostic evaluation. Key strengths were the use of existing health infrastructure, and decentralization of services. However, challenges were identified in HPV test procurement, referral pathways, quality of pathology and colposcopy, and adequate data collection. Addressing these issues is critical to the future success of cervical cancer screening in Uzbekistan.


  • Open Access

    Clinical validation of four point-of-care high-risk HPV assays, including two reduced-valency assays, for cervical cancer screening in low-resource settings

    by Neerja Bhatla, MaryLuz ROL, Seema Singhal, Showket Hussain, Anushree Patil, Pranay Tanwar, Shalini Singh, Vikrant M Bhor, Kiran Munne, Richa Vashishtha, et al.

  • Open Access

    CanScreen5, a global repository for breast, cervical and colorectal cancer screening programs

    by Li Zhang, Isabel Mosquera, Eric Lucas, Mary Luz Rol, Andre L. Carvalho, Partha Basu

    The CanScreen5 project is a global cancer screening data repository that aims to report the status and performance of breast, cervical and colorectal cancer screening programs using a harmonized set of criteria and indicators. Data collected mainly from the Ministry of Health in each country underwent quality validation and ultimately became publicly available through a Web-based portal. Until September 2022, 84 participating countries reported data for breast (n = 57), cervical (n = 75) or colorectal (n = 51) cancer screening programs in the repository. Substantial heterogeneity was observed regarding program organization and performance. Reported screening coverage ranged from 1.7% (Bangladesh) to 85.5% (England, United Kingdom) for breast cancer, from 2.1% (Côte d’Ivoire) to 86.3% (Sweden) for cervical cancer, and from 0.6% (Hungary) to 64.5% (the Netherlands) for colorectal cancer screening programs. Large variability was observed regarding compliance to further assessment of screening programs and detection rates reported for precancers and cancers. A concern is lack of data to estimate performance indicators across the screening continuum. This underscores the need for programs to incorporate quality assurance protocols supported by robust information systems. Program organization requires improvement in resource-limited settings, where screening is likely to be resource-stratified and tailored to country-specific situations.


  • A blinded randomized phase 2/3 study of the efficacy and safety of intravenous DNL310 (brain-penetrant enzyme replacement therapy) in MPS II

    by Jeffrey Harris, Yuda Zhu, Judy Ho, Charlene Chen, Anna Bakardjiev, Fabian Model, Matthew Troyer, Carole Ho, Peter Chin